These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3326625)

  • 1. Anti-infectious responses in Leishmania major-infected BALB/c mice injected with recombinant granulocyte-macrophage colony-stimulating factor.
    Solbach W; Greil J; Röllinghoff M
    Ann Inst Pasteur Immunol; 1987; 138(5):759-62. PubMed ID: 3326625
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of recombinant granulocyte-macrophage colony-stimulating factor has a detrimental effect in experimental murine leishmaniasis.
    Greil J; Bodendorfer B; Röllinghoff M; Solbach W
    Eur J Immunol; 1988 Oct; 18(10):1527-33. PubMed ID: 3142778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colony-stimulating factors in parasitic diseases.
    Reed SG
    Diagn Microbiol Infect Dis; 1990; 13(5):387-9. PubMed ID: 2126497
    [No Abstract]   [Full Text] [Related]  

  • 4. GM-CSF produced by recombinant vaccinia virus or in GM-CSF transgenic mice has no effect in vivo on murine cutaneous leishmaniasis.
    Corcoran LM; Metcalf D; Edwards SJ; Handman E
    J Parasitol; 1988 Oct; 74(5):763-7. PubMed ID: 3047351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of granulocyte-macrophage colony-stimulating factor in the pathogenesis of experimental murine leishmaniasis.
    Solbach W; Bodendorfer B; Greil J; Röllinghoff M
    Mem Inst Oswaldo Cruz; 1988 Nov; 83 Suppl 1():407-10. PubMed ID: 3075683
    [No Abstract]   [Full Text] [Related]  

  • 6. Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3.
    Feng ZY; Louis J; Kindler V; Pedrazzini T; Eliason JF; Behin R; Vassalli P
    Eur J Immunol; 1988 Aug; 18(8):1245-51. PubMed ID: 2970970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human granulocyte-macrophage colony-stimulating factor in AIDS.
    N Engl J Med; 1988 Mar; 318(9):579-80. PubMed ID: 3277058
    [No Abstract]   [Full Text] [Related]  

  • 8. Th2 lymphocyte clone can activate macrophage antileishmanial defense by a lymphokine-independent mechanism in vitro and can augment parasite attrition in vivo.
    Sypek JP; Matzilevich MM; Wyler DJ
    Cell Immunol; 1991 Mar; 133(1):178-86. PubMed ID: 1825032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor.
    Neta R; Oppenheim JJ; Douches SD
    J Immunol; 1988 Jan; 140(1):108-11. PubMed ID: 2447166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-macrophage colony-stimulating factor and marrow transplantation.
    Sauter C
    N Engl J Med; 1988 Sep; 319(13):870-1. PubMed ID: 3045556
    [No Abstract]   [Full Text] [Related]  

  • 11. Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes.
    N Engl J Med; 1988 Jul; 319(1):51-3. PubMed ID: 3288869
    [No Abstract]   [Full Text] [Related]  

  • 12. Lowering cholesterol with granulocyte-macrophage colony-stimulating factor.
    JAMA; 1989 Apr; 261(16):2331-2. PubMed ID: 2649696
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical studies of granulocyte-macrophage colony stimulating factor.
    Gutterman J
    Semin Oncol; 1988 Oct; 15(5 Suppl 5):52-3. PubMed ID: 3057645
    [No Abstract]   [Full Text] [Related]  

  • 14. Agranulocytosis associated with T-gamma-lymphocytosis: no improvement of peripheral blood granulocyte count with human-recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF).
    Thomssen C; Nissen C; Gratwohl A; Tichelli A; Stern A
    Br J Haematol; 1989 Jan; 71(1):157-8. PubMed ID: 2644967
    [No Abstract]   [Full Text] [Related]  

  • 15. Early clinical trials with colony-stimulating factors.
    Morstyn G; Lieschke GJ; Cebon J; Dührsen U; Villeval JL; Sheridan W; McGrath K; Layton JE
    Cancer Invest; 1989; 7(5):443-56. PubMed ID: 2482790
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic uses of macrophage colony-stimulating factor.
    Nadler PI
    Cancer Invest; 1990; 8(2):299-300. PubMed ID: 2205341
    [No Abstract]   [Full Text] [Related]  

  • 17. A model for the mechanism of sensitivity of BALB/c mice to L. major and premunition in leishmaniasis.
    Modabber F
    Ann Inst Pasteur Immunol; 1987; 138(5):781-6. PubMed ID: 3440062
    [No Abstract]   [Full Text] [Related]  

  • 18. [Expectations in the clinical application of human-recombinant cytokines. 4) Interleukin-3 and colony-stimulation factors].
    Takaku F
    Nihon Rinsho; 1988 May; 46(5):1105-11. PubMed ID: 2457722
    [No Abstract]   [Full Text] [Related]  

  • 19. Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice.
    Rostamian M; Sohrabi S; Kavosifard H; Niknam HM
    J Microbiol Immunol Infect; 2017 Apr; 50(2):160-166. PubMed ID: 26066544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GM-CSF: granulocyte and macrophage colony stimulating factor. A biologic agent with a great therapeutic potential in oncology].
    Cortes-Funes H
    Rev Clin Esp; 1990 Mar; 186(4):173-4. PubMed ID: 2195605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.